• Alicia L Agnoli, Rebecca Howe, Elizabeth Magnan, Anthony Jerant, Daniel Colby, and Peter Franks.
• From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC). aagnoli@ucdavis.edu.
• J Am Board Fam Med. 2023 Aug 9; 36 (4): 537541537-541.

IntroductionNational guidelines recommend that patients with chronic noncancer pain prescribed long-term opioid therapy (LTOT) undergo periodic urine drug testing (UDT), yet UDT is performed inconsistently, and little evidence supports the utility of this approach. We examined patient and prescriber factors associated with UDT.MethodsA 1-year retrospective cohort study of 5690 patients prescribed LTOT by 689 clinicians in a network of 13 primary care and specialty clinics. Negative binomial regression examined patient and prescriber factors associated with the number of tests completed, and logistic regression examined prescriber and practice level testing likelihood. Analyses were adjusted for patient and clinician characteristics and accounted for patient clustering within prescribers.ResultsA total of 2256 patients (39.6%) had UDT completed at least once. More UDT completion was associated with Black patient race and receipt of more opioid prescriptions, as well as with clinician testing compliance.ConclusionsUDT was relatively infrequent in patients prescribed LTOT and associated with patient factors not known to confer greater opioid-related risk, such as race. In addition, there was significant clinician-driven variation in UDT. Given the uncertain clinical utility of such testing, these findings signal the need for strategies to address potential biases in the use of UDT.© Copyright by the American Board of Family Medicine.

19 keywords...

hide…